Alkermes plc (NASDAQ:ALKS) belonging to the Medical sector has declined -4.67% and closed its last trading session at $55.55.
The company reported its EPS on 11/02/2016. Currently, the stock has a 1 Year Price Target of $65.27.
The consensus recommendation, according to Zacks Investment research, is 1.55. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell. The Stock had a 1.55 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 1.88 and 1.83 respectively.
Alkermes plc on 11/02/2016 reported its EPS as $-0.09 with the analysts projecting the EPS of the stock as $-0.06. The company beat the analyst EPS Estimate with the difference of $-0.03. This shows a surprise factor of -50%.
Many analysts have provided their estimated foresights on Alkermes plc Earnings, with 9 analysts believing the company would generate an Average Estimate of $0.04. Whereas they predicted High and Low Earnings Estimate as $0.1 and $-0.05 respectively. While in the same Quarter Previous year, the Actual EPS was $-0.14.
Analysts are also projecting an Average Revenue Estimate for Alkermes plc as $207.37 Million in the Current Quarter. This estimate is provided by 8 analysts. The High Revenue estimate is predicted as 218 Million, while the Low Revenue Estimate prediction stands at 198.6 Million. The company’s last year sales total was 163.1 Million.
For the Current Quarter, the growth estimate for Alkermes plc is 128.6%, while for the Next Quarter the stock growth estimate is 33.3%. In the past 5 years, the stock showed growth of -50.83% per annum. While for the next 5 years, the growth estimate is -28.41%.
The Company got Upgrade by JP Morgan on 21-Oct-16 from Neutral to Overweight.
Insider Trades for Alkermes plc show that the latest trade was made on 30 Nov 2016 where Biberstein (Kathryn L), the Officer completed a transaction type “Sell” in which 7933 shares were traded at a price of $55.69.
39 Insider Sales transactions were made totaling 535090 shares traded.
11 analysts projected Price Targets for Alkermes plc. The analysts believe that the company stock price could grow as high as $78. The Low Price target projection by analysts is $48 and the Mean Price Target is $65.27.
Alkermes plc (NASDAQ:ALKS) has the market capitalization of $8.42 Billion. The company rocked its 52-Week High of $80.71 on Dec 29, 2015 and touched its 52-Week Low of $27.14 on Mar 17, 2016. The stock has Return on Assets (ROA) of -14.4 percent. Return on Equity (ROE) stands at -20.4% and Return on Investment (ROI) of -13.7 percent.
The stock is currently showing YTD performance of -30.02 Percent. The company has Beta Value of 2.16 and ATR value of 2.17. The Weekly and Monthly Volatility stands at 4.20% and 3.51%.
Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPERDAL CONSTA, the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and marketed worldwide by Janssen-Cilag, a wholly owned division of Johnson & Johnson; and VIVITROL the first and only once-monthly injectable medication approved for the treatment of alcohol dependence and marketed in the U.S. primarily by Cephalon, Inc. Alkermes’ pipeline includes extended-release injectable, pulmonary, and oral products for the treatment of prevalent, chronic diseases such as central nervous system disorders, addiction and diabetes.